UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Long-term Amvuttra benefits hATTR-PN patients, trial data show

Source
Amyloidosis News Today

Long-term treatment with Amvuttra (vutrisiran) was found to be safe and to sustain disease stability in people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN).

That’s according to up to five years of data from the Phase 3 HELIOS-A clinical trial (NCT03759379), in which patients showed a sustained improvement in nerve function, mobility, and quality of life.

These results “demonstrate relative stability with only modest changes in disease activity, sustained [reductions in the faulty transthyretin, or TTR, protein], and an acceptable safety profile with long-term [Amvuttra] treatment in patients with [hATTR-PN],” the researchers wrote.